

UTILITY PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATL. STAGE
APPLICATION OF : Rakoczi, et al.

TITLE : **ORGANIC COMPOUNDS**

SERIAL NO. : 10/565,520

US FILING OR 371C DATE : July 28, 2004

ATTORNEY DOCKET NO. : H-33238A

CONFIRMATION NO. : 2957

ART UNIT : 1616

EXAMINER : Frank I. Choi

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

1. This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§§ 1.56, 1.97 and 1.98. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

2. Pursuant to 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

3. Pursuant to 37 C.F.R. § 1.97(h), the filing of this Information Disclosure Statement shall not be construed as an admission that the information cited in this Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

4. Regarding each listed document that is not in the English language, an English-language translation accompanies this Statement as indicated on the attached PTO-1449 or a concise explanation of the relevance of the document is set forth in the following document(s):

(X) Translation to English of document sections considered to possibly be relevant.

5. Pursuant to 37 C.F.R. § 1.97(b) this Statement is being filed:


- () within 3 months of the filing date of a national application; or
- () within 3 months of the date of the entry of the national stage as set forth in 37 CFR § 1.491 in an international application; or
- (X) before the mailing date of a first Office Action on the merits.

The Commissioner is hereby authorized to charge any additional fees required for consideration of this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-4389, identifying our Docket No. H-33238A.

Respectfully submitted,

Dated: March 19, 2010

By:


Todd Sladek

Registration No. 53,768
Tel: 336-387-1601

Novartis Animal Health US, Inc.
3200 Northline Ave., Ste. 300
Greensboro, NC 27408